In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis

Clinical Therapeutics

Volumn 26, Issue 8, 2004, Pages 1261-1273

  De Clerck, Fred ^a,b,d   Somers, Yves ^a   Mannaert, Erik ^a   Greenspan, Andrew ^c   Eerdekens, Marielle ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d Turnhoutseweg 30 B 2340 Beerse B ^*  (United States)

Author keywords

9 hydroxy risperidone; plasma coagulation fibrinolysis; platelets; risperidone; thromboembolism

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; APROTININ; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONIC ACID; CLONIDINE; COLLAGEN; DIMETHYL SULFOXIDE; ERGOTAMINE; HEPARIN; MILRINONE; PALIPERIDONE; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN SYNTHASE; RISPERIDONE; SEROTONIN; SUPROFEN; THROMBOXANE SYNTHASE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; DIAGNOSTIC AGENT; ISOXAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ADULT; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE; VASCULAR RING; ANIMAL; AORTA; BLOOD CLOTTING TEST; METABOLISM; REFERENCE VALUE; WISTAR RAT;

ADULT; ANIMALS; AORTA; ARACHIDONIC ACID; BLOOD COAGULATION TESTS; CLONIDINE; EPINEPHRINE; ERGOTAMINE; FIBRINOLYSIS; HUMANS; ISOXAZOLES; MALE; MILRINONE; PLATELET AGGREGATION; PYRIMIDINES; RATS; RATS, WISTAR; REFERENCE VALUES; RISPERIDONE; SEROTONIN; SEROTONIN ANTAGONISTS; SUPROFEN;

EID: 6344276723     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)80097-3     Document Type: Article

References (49)

1. Hagg S, and Spigset O Antipsychotic-induced venous thromboembolism: A review of the evidence CNS Drugs 16 2002 765 776
2. Zornberg GL, and Jick H Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: A case-control study Lancet 356 2000 1219 1223
3. Zornberg GL, and Jick H Authors' response to Tipper et al and Hardwick and Ferguson Lancet 357 2000 391 392
4. Tapson VE Risk of venous thromboembolism with use of antipsychotic drugs Lancet 356 2000 1206
5. Letter Tipper R, Hare E, and Kondracki S Antipsychotic drugs and venous thromboembolism Lancet 357 2001 391
6. Letter Hardwick JC, and Ferguson EJ Antipsychotic drugs and venous thromboembolism Lancet 357 2001 391
7. Thomassen R, Vandenbroucke JP, and Rosendaal FR Antipsychotic medication and venous thrombosis Br J Psychiatry 179 2001 63 66
8. Thomassen R, Vandenbroucke JP, and Rosendaal FR Antipsychotic drugs and venous thromboembolism Lancet 356 2000 252
9. Kamijo Y, Soma K, and Nagai T Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines Circ J 67 2003 46 48
10. Walker AM, Lanza LL, Arellano F, and Rothman KJ Mortality in current and former users of clozapine Epidemiology 8 1997 671 677
11. Hagg S, Spigser O, and Soderstrom TG Association of venous thromboembolism and clozapine Lancet 355 2000 1155 1156
12. Wolstein J, Grohman R, Ruther H, and Hippius H Antipsychotic drugs and venous thromboembolism Lancet 356 2000 252
13. Wooltorton E Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials CMAJ 167 2002 1269 1270
14. Poster Greenspan A, Eerdekens M, and Mahmoud R Risk of cerebrovascular adverse events, including mortality, with risperidone in elderly patients Int Psychogeriatrics 15 Suppl 2 2003 261 262
15. Hagg S, Tatting P, and Spigset O Olanzapine and venous thromboembolism Int Clin Psychopharmacol 18 2003 299 300
16. Waage IM, and Gedde-Dahl A Pulmonary embolism possibly associated with olanzapine treatment BMJ 327 2003 1384
17. Zyprexa (olanzapine) tablets 2004 Eli Lilly and Company New York, NY
18. Wooltorton E Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials CMAJ 170 2004 1395
19. 2 in ischaemic heart disease Blood Coagul Fibrinolysis 1 1990 201 209
20. Mustard JF, Packham MA, and Kinlough-Rathbone RL Mechanisms in thrombosis Bloom AL Thomas DP Haemostasis and Thrombosis 1981 Churchill Livingstone Indianapolis, Ind. 503 526
21. Grant S, and Fitton A Risperidone A review of its pharmacology and therapeutic potential in the treatment of schizophrenia Drugs 48 1994 253 273
22. 2 receptors Int Clin Psychopharmacol 10 1995 19 30
23. 2/prostaglandin endoperoxide receptor blockade combined in one molecule - I. Biochemical profile in vitro Thromb Haemost 61 1989 35 42
24. 2/prostaglandin endoperoxide receptor blockade combined in one molecule-II. Pharmacological effects in vitro and ex vivo Thromb Haemost 61 1989 43 49
25. De Clerck F, Xhonneux B, and de Chaffoy de Courcelles D Functional expression of the amplification reaction between serotonin and epinephrine on platelets J Cardiovasc Pharmacol 11 Suppl 1 1988 S1 S5
26. 2 receptor sites on human blood platelets Biochem Pharmacol 33 1984 2807 2811
27. De Clerck F Human platelet aggregation induced by 5-hydroxytryptamine: A methodological study Hematol Rev 2 1988 197 262
28. Caen J, Larrieu MJ, and Samama M Ehemostase. Methodes d'Exploration et Diagnostique Pratique 1968 LExpansion Scientifique New York
29. Sun J, Abel EW, and Bancroft A A study of whole blood platelet and white cell aggregation using a laser flow aggregometer Platelets 14 2003 103 108
30. Zahn R, Beeck H, and Winkelmann BR Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease Blood Coagul Fibrinolysis 13 2002 81 87
31. Heit JA, Silverstein MD, and Mohr DN The epidemiology of venous thromboembolism in the community Thromb Haemost 86 2001 452 463
32. Silberstein SD, and McCrory DC Ergotamine and dihydroergotamine: History, pharmacology, and efficacy Headache 43 2003 144 146
33. Van Zwieten PA Antihypertensive drugs interacting with the sympathetic nervous system and its receptors Antonaccio MJ Cardiovascular Pharmacology 1990 Raven Press Paris 37 73
34. Manns JM, Brenna KJ, Colman RW, and Sheth SB Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases Thromb Haemost 87 2002 873 879
35. Fitzgerald GA Cardiovascular pharmacology of non-selective nonsteroidal anti-inflammatory drugs and coxibs: Clinical considerations Am J Cardiol 89 2002 26D 32D
36. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Res. Available at: http: //www.science.com/science/article/B6TC24BT8MM21/2/ 6c403d81b55946e0d29d74a15f3c00a.
37. Yasui-Furukori N, Hidestrand M, and Spina E Differential enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug Metab Dispos 29 2001 1263 1268
38. Yasui-Furukori N, Mihara K, and Kondo T Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia J Clin Pharmacol 43 2003 122 127
39. (Suppl) Heykants J, Huang ML, and Mannens G The pharmacokinetics of risperidone in humans: A summary J Clin Psychiatry 55 1994 13 17
40. Draper NR, and Smith M Applied Regression Analysis 1981 Wiley New York
41. Roevens P, and de Chaffoy de Courcelles D Desensitization and resensitization of human platelets to 5-hydroxytryptamine at the level of signal transduction Biochem J 307 1995 775 782
42. The PACK Trial Group Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis A multi-center, double-blind, placebo-controlled trial Thromb Res 55 1989 13 23
43. Ishigooka J, Shizu Y, and Wakatabe H Different effects of centrally acting drugs on rabbit platelet aggregation: With special reference to selective inhibitory effects of antipsychotics and antidepressants Biol Psychiatry 20 1985 866 873
44. Govitrapong P, Chagkutip J, Turakitwanakan W, and Srikiathachom A Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment Psychiatry Res 96 2000 41 50
45. 2A receptor density but not second messenger inositol triphosphate levels in drug-free schizophrenic patients Psychiatry Res 118 2003 165 174
46. Thorup M, and Fog R Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors Acta Psychiatr Scand 55 1977 123 126
47. Arora RC, and Meltzer HY Effects of clozapine treatment on serotonin-2-receptor binding in the blood platelets of schizophrenic patients Neuropsychopharmacology 10 1994 109 114
48. Ereshefsky L, Riesenman C, True JE, and Javors M Serotonin-mediated increase in cytosolic [Ca++] in platelets of risperidone-treated schizophrenia patients Psychopharmacol Bull 32 1996 101 106
49. Boullin DJ, Know JM, and Peters JR Platelet aggregation and chlorpromazine therapy Br J Clin Pharmacol 6 1978 538 540